Home > Companies > Biocant - Technology Transfer Association

Biocant - Technology Transfer Association

BIOCANT Park is the first Portuguese venue entirely devoted to Biotechnology. Here, advanced Life Sciences knowledge and technology are developed and applied creating value in business initiatives. Through an audacious investment by the Municipality of Cantanhede and by the Center for Neuroscience and Cell Biology of Coimbra, and taking advantage of the last years’ national investment in Life Sciences, it was possible to set out an integrated development strategy to promote entrepreneurship and economic growth. The core of the Park is the R&D center – BIOCANT, Biotechnology Innovation Center – where specialized research teams use their built-up scientific competences to generate novel services and products. The scientific units of BIOCANT have committed staff and state-of-the-art equipment with high-throughput capacity.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

2nd International Conference on Metabolomics and metabolism

Conference

CMC PROGRESSION FROM EARLY TO LATE PHASE – PRACTICAL CONSIDERATIONS FOR GENE THERAPY

Webinar

Plant Cell & Tissue Culture In Vitro IV

Conference

Deuel Conference on Lipids

Conference

18th International Conference on Metabolomics and Systems Biology

Conference

16th International Conference on Lipid Science and Technology

Conference

Related News

MEDICAL

SLATE BIO ANNOUNCES THE LAUNCH WITH SEED FINANCING TO DEVELOP NEXT GENERATION IL-2 THERAPIES

Slate Bio | January 20, 2021

Slate Bio, Inc., reports the closing of a $1.75 million venture financing. Epidarex Capital drove the speculation round with cooperation from the UVA Licensing and Ventures Group Seed Fund, Center for Innovative Technology's GAP BioLife Fund, VTC Seed Fund, PharmaDirections, Inc., the board and others. Record is a pre-clinical biotechnology organization creating outlook changing IL-2 mixes dependent on examination directed at the University of Virginia School of Medicine. IL233, Slate's ...

CELL AND GENE THERAPY

VIZGEN RELEASES COMMERCIAL MERSCOPE PLATFORM

Vizgen | August 31, 2021

Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced shipment of the first commercial MERSCOPETM Platforms, marking the successful start of their limited summer release program. These first platforms are being purchased by leading research institutes including the Salk Institute, the University of California, Irvine, and the Beth Israel Deaconess Medical Center. Vizgen will continue shipping a limited number...

MEDTECH

AESTHETICS BIOMEDICAL® ANNOUNCES COLLABORATION WITH U.S. DERMATOLOGY PARTNERS OFFERING CONSUMERS LUXURY EXPERIENTIAL AESTHETIC TREATMENTS

Aesthetics Biomedical® Inc. | October 07, 2021

Aesthetics Biomedical® Inc. (ABM), is pleased to announce their long-term partnership with U.S. Dermatology Partners, the largest physician-led dermatology practice in the United States. With years of experience and more than 90+ locations throughout Arizona, Colorado, Kansas, Maryland, Missouri, Oklahoma, Texas, and Virginia, U.S. Dermatology Partners combines the personal level of care found in private dermatology practices with the benefits of a network of physician experts...

CYTODYN ANNOUNCES FIRST SITE IN THE SOUTHEASTERN USA TO ENROLL PATIENTS IN PHASE 2 CORONAVIRUS TRIAL

Proactive Investors | April 08, 2020

The Novant Health network cares for around 5 million patients a year at nearly 700 locations, including 15 hospitals and hundreds of outpatient facilities and physician clinics. CytoDyn Inc (OTCQB:CYDY), the late stage biotech, said partner Novant Health has started enrolling patients in the company's Phase 2 randomized clinical trial using leronlimab for coronavirus (COVID-19) patients with mild-to-moderate symptoms. Novant Health is the second trial site in the USA and the first site in th...

MEDICAL